Clinical Trial Update: Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers [Phase 1]

View source ↗

Summary

A Phase 1 study of AMG 199 in MUC17-positive solid tumors including gastric, gastroesophageal junction, colorectal, and pancreatic cancers has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Gastric Cancer
• Gastroesophageal Junction Cancer
• Pancreatic Cancer

Drugs mentioned

• AMG 199

Snippet

Sponsor: Amgen | Conditions: MUC17-positive Solid Tumors | Phase 1 | Status: TERMINATED